Prof Per-Anders Abrahamsson - Lund University, Malmö, Sweden
Proudly Sponsored by
Dr. Per-Anders Abrahamsson is currently Professor and Past Chairman of the Department of Urology, Lund University, Malmö, Sweden. Professor Abrahamsson is also an Adjunct Professor in Urology at the University of Rochester Medical Center, New York, USA. He qualified in medicine at Lund University in 1977 and completed his PhD at the same institution in 1988.
Professor Abrahamsson has published over 300 peer-reviewed articles and over 80 book chapters in the field of urology, mainly prostatic diseases. He has been the Secretary General the European Association of Urology (EAU; 2007 – 2015). He also serves on the editorial boards of several scientific journals and is frequently invited to speak at International meetings, receiving several prizes for his presentations. He is also Honourable Professor – Doctor Honoris Causa – at 7 European Institutions. In addition, Honorary Member of 15 Scientific organisations. Professor Abrahamsson has received numerous national and international awards during his career, including the Polish Red Cross for humanitarian support and, most recently, the International Society of Urology’s (SIU) Distinguished Career Award in 2011. Finally, the highest award – Schlomo Raz Award – delivered 2014 by Confederación Americana de Urología (CAU) and Frans Debruyne Life Time Achievement Award by EAU 2016.
Dr Jeffrey Cadeddu - Southwestern Medical Center, United States
Jeffrey Cadeddu, M.D., is one of Texas’ leading urologists in the surgical treatment of prostate and kidney disorders. As Director of the UT Southwestern Clinical Center for Minimally Invasive Treatment of Urologic Cancer, he has performed more than 500 robotic/laparoscopic procedures on the prostate and introduced a number of firsts in the minimally invasive surgical treatment of kidney cancer and kidney disease.
His training and extensive experience with kidney cancers in particular allow him to offer patients the full gamut of options in managing the disease without losing the kidney. Those options include ablation, an outpatient procedure in which the tumor is destroyed with a heated probe, rather than removed surgically. Dr. Cadeddu was the first in Texas to perform the procedure. He also has the most experience in North Texas with laparoscopic and robotic partial nephrectomy to remove kidney cancers.
Along with an active clinical practice focused on minimally invasive procedures, Dr. Cadeddu maintains a robust research program aimed at developing new technologies and techniques that will make kidney surgery even less invasive while also maximizing kidney function better than what has traditionally been done.
Dr. Cadeddu joined the faculty of UT Southwestern Medical Center, where he is a Professor of Urology and Radiology, in 1999 after receiving his initial medical training and completing residencies in urology and surgery at Johns Hopkins School of Medicine in Baltimore.
As an expert in the treatment of kidney and prostate diseases, Dr. Cadeddu regularly lectures and educates other medical professionals on the latest developments in managing urologic conditions. In 2007, he received the Gold Cystoscope Award from the American Urological Association for his contributions to advances in kidney cancer treatment and the training of numerous academic urologists.
Dr Peter Carroll - University of California, San Francisco, United States
Dr. Peter Carroll, is professor and chair of the Department of Urology at University of California, San Francisco. He received his medical degree from Georgetown University, completed residency at UCSF, his fellowship at Memorial-Sloan Kettering, and MPH from UC Berkeley. He holds the Ken and Donna Derr-Chevron Distinguished Professorship in Urology and is the winner of numerous awards including the coveted Barringer Medal. Dr. Carroll is committed to reducing the burden of prostate cancer treatment – physical, psychological, and monetary. He pioneered and remains a vocal advocate for standardising an active surveillance regimen in patients with low-volume, early stage prostate cancer.
Dr William Catalona - Northwestern University Feinberg School of Medicine, United States
Dr. Catalona is known for having been the first to show that the prostate-specific antigen (PSA) blood test can be used as a first-line screening test for the early detection of prostate cancer and for having developed and conducted the pivotal studies that lead to the U.S. Food and Drug Administration approval of PSA testing for early detection of prostate cancer and the “free” PSA test and the Prostate Health Index (PHI) test as means of improving the accuracy of prostate cancer screening. He is the Principal Investigator on the Northwestern University-based Prostate SPORE grant and co-investigator on two other NIH grants as well as a Prostate Cancer Foundation Challenge Award. He is currently conducting research into the genetics of prostate cancer. He specializes in prostate cancer surgery and is recognized as an expert in performing the “nerve-sparing” radical retropubic prostatectomy.
In addition to his appointment as Professor of Urology, Dr. Catalona also serves as Director of the Clinical Prostate Cancer Program of Northwestern’s Robert H. Lurie Comprehensive Cancer Center.
Dr Brian Chapin - UT MD Anderson Cancer Centre, United States
Dr. Brian Chapin is an Assistant Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center. He provides complete surgical care for men and women diagnosed with urologic malignancies. He performs open surgery and minimally invasive/robotic surgery, for patients with prostate, kidney, bladder and testis cancers. His major clinical focus is on the treatment of high risk localised, locally advanced and metastatic prostate cancers.
He has active clinical research protocols developing the integration of surgical, radiation and medical therapies in the treatment of advanced prostate cancer. Dr. Chapin is involved with the basic science/translational research program at M.D Anderson, which is attempting to identify the immunologic changes that occur with surgical and systemic therapy treatments in advanced prostate cancer and how these changes may be exploited with use of newer immune modulating therapies. Using a comprehensive multimodality approach to this disease, Dr. Chapin’s goal is to ease suffering and prolong survival in men with advanced prostate cancer.
Ms Louisa Fleure - Guys Hospital, United Kingdom
Louisa is Lead Urology Clinical Nurse Specialist at Guy’s and St Thomas’, London with special interests in advanced prostate cancer, androgen deprivation therapy and survivorship. She completed her BSc (Hons) nursing in 1990, before completing her PGdip health care ethics and MSc in advancing healthcare practice at King’s College London. She has a graduate diploma in law and is a non-medical prescriber.
Dr Celestia Higano - University of Washington, United States
Dr Higano is a Professor in the Departments of Medicine (Division of Oncology) and Urology at the University of Washington and is a Member of the Clinical Division at Fred Hutchinson Cancer Research Center. Her research interests focus on new drug development including immunotherapy, the effects of androgen deprivation therapy on the male body and mind, and development of supportive care/survivorship programs for prostate cancer patients and their partners.
Prof Guido Jenster - Erasmus MC, Netherlands
Guido Jenster received his PhD in 1994 at the Erasmus University Rotterdam on mapping of the functional domains of the human androgen receptor. As a postdoctoral associate at Baylor College of Medicine, Houston, he worked on the newly identified steroid receptor coactivators. As an Assistant Professor of Urology at the University of Texas M.D. Anderson Cancer Center, Houston and since 1999 at the Erasmus MC, he started his work on the role of genes and pathways in prostate cancer. In the last decade and as Professor of Experimental Urological Oncology, the research focus has been extended with the identification of novel biomarkers for prostate cancer, particularly the RNAs and proteins present in cancer-derived extracellular vesicles.
Dr Steven Kaplan - Icahn School of Medicine at Mount Sinai, United States
Dr. Steven Kaplan is Director of the Men’s Wellness Program, Mount Sinai Health System and Professor, Icahn School of Medicine at Mount Sinai. He is an internationally renowned authority and one of the primary thought leaders in the study of benign diseases, the association of metabolic factors with voiding dysfunction, and female urology, with symptoms related to both benign prostate enlargement and bladder function.
Dr. Kaplan is a Diplomat of the American Board of Urology and a Fellow of the American College of Surgeons. His landmark study, published in JAMA in 2006, changed the way medications are used in the treatment of men with symptoms related to both benign prostate enlargement and bladder dysfunction.
He serves as both member and / or Chair of numerous study sections for the NIH and more recently, he chaired the NIDDK Prostate Strategic Planning Committee and currently Chairs the AUA Research Committee on Advocacy. He also has served on the American Urologic Association Guidelines Panel for BPH. He was awarded the John K. Lattimer Award for Lifetime Achievement in Urology by the National Kidney Foundation.
Dr. Kaplan joined Mount Sinai from Weill Cornell Medical College, where he held the tenured position of E. Darracott Vaughan, Jr. Professor of Urology as well as Director of the Iris Cantor Men’s Health Center. Prior to this, he held the tenured position of Given Foundation Professor of Urology at Columbia University and was the Vice Chairman and Program Director.
Dr Stacy Loeb - New York University, United States
Assistant Professor of Urology and Population Health, New York University, NY, USA
Dr. Stacy Loeb is an Assistant Professor of Urology and Population Health at New York University (NYU), specialising in prostate cancer. Dr. Loeb attended medical school at Northwestern University and completed her urology residency training at Johns Hopkins. She has published over 220 peer-reviewed articles and 8 book chapters on prostate cancer. Dr. Loeb is on the Editorial Board for the British Journal of Urology International, European Urology, Urology Practice, and Reviews in Urology, and authored the chapter on “Early Detection, Diagnosis, and Staging of Prostate Cancer” for Campbell-Walsh Urology. She also helps teach several courses on prostate cancer for other urologists, and hosts the Men’s Health Show on SiriusXM USA/Canadian satellite radio. Dr. Loeb has a grant from the National Cancer Institute to study the optimal approach to active surveillance.
Professor Tom Pickles - BC Cancer Agency, Canada
Clinical interests include prostate cancer (active surveillance, and brachytherapy), lymphoid malignancies including radio-immunotherapy, and particle therapy. Research interests include doctor-patient communication, population-based outcomes analysis and PSA kinetics. Past-president of the Canadian Association of Radiation Oncology 2006-8, and chair of the BC Cancer Genito-Urinary Tumour Group 2000-6.
Dr Oliver Altonn Sartor - Depts. Of Medicine & Urology Tulane Medical School, United States
Proudly Sponsored by
Dr. Oliver Sartor is an internationally recognised expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI).
He has published over 300 articles and book chapters and led multiple national and international clinical trials as either a principal investigator or co-principal investigator. In particular he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel. He has lectured widely, and at last count has given invited lectures in 28 countries. He is currently the Medical Director of the Tulane Cancer Center and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments.
He has served as the past Chairman of the Department of Defence Prostate Cancer Integration Panel, is currently Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG. He is also currently a member of the NCI Board of Scientific Counsellors (Clinical Sciences and Epidemiology).
Prof Joseph Smith - Vanderbilt University in Nashville, Tennessee, United States
Joseph A Smith, Jr. is William L. Bray Professor in the Department of Urologic Surgery at Vanderbilt University in Nashville, Tennessee. He served as Chairman of the department from 1991 to 2015. He is an AOA graduate of the University of Tennessee Medical School and was chosen the Outstanding Graduate. He performed his surgery residency at the University of Texas Southwestern Medical School at Dallas, his urology residency at the University of Utah, and a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York.
Dr. Smith has served as President of the American Board of Urology, President of the Society of Urologic Oncology, President of the Southeastern Section of the American Urologic Association, and Chairman of the Residency Review Committee for Urology. He is a recipient of the Distinguished Contribution Award and the Hugh Hampton Young Award from the American Urologic Association, the SUO Achievement Medal and the Huggins Medal from the Society of Urologic Oncology, the St. Paul Medal from the British Association of Urologic Surgeons, the Albert Schweitzer Medal from the Societe Internationale d’Urologie, and the Valentine Medal from the New York Academy of Medicine. He is a member of the American Association of Genitourinary Surgeons and the Clinical Society of GU Surgeons. He was awarded the Outstanding Alumnus Award from the University of Tennessee. Dr. Smith is Editor of the Journal of Urology, the most widely read and highly cited journal in the specialty. He has been listed on Castle Connelly prestigious “Best Doctors” list for 25 consecutive years and was designated by Time Magazine as one of the top five surgeons in the country for treatment of cancer.
He has published over 300 peer reviewed manuscripts, over 100 book chapters, and has edited or co-edited eight textbooks including the third and fourth editions of Hinman’s Atlas of Urologic Surgery. His professional focus has been on innovative treatment strategies for patients with urologic cancers and introduction and evaluation of technologic advances in urologic surgery. He has performed over 1,000 radical cystectomies and 8,000 radical prostatectomies.
Dr Brantley Thrasher - The University of Kansas Physicians, United States
Dr. J. Brantley Thrasher is the William L. Valk Distinguished Professor, Department of Urology and the Co-Director of Operative Services at the University of Kansas Medical Center in Kansas City, Kansas. He completed his Medical Degree at the Medical University of South Carolina in Charleston, South Carolina, an internship at Walter Reed Army Medical Center in Washington D.C., and his urology residency at Fitzsimons Army Medical Center in Aurora, Colorado. He subsequently completed a urologic oncology fellowship at Duke University Medical Center. He served for three years as Program Director for the Urology Residency Program at Madigan Army Medical Center in Tacoma, Washington, and after completing his military obligation, he was appointed to his present position in 1998.
He is the President of the American Board of Urology, President of the Society of Urology Chairpersons and Program Directors, immediate Past-President of the Society of Urologic Oncology (SUO), and a member of the Residency Review Committee for Urology. He served as the South Central Section Representative to the American Urological Association (AUA) Board of Directors, and is the President-elect of the AUA. He is a Diplomat of the American Board of Urology, a Fellow of the American College of Surgeons, and a member of the American Association of Genitourinary Surgeons. This year, he was awarded the Distinguished Service Award from the AUA, for 15 years of service to academic and organized urology.
Dr. Thrasher’s basic science research interests in the area of prostate cancer and he is currently a co-investigator or consultant in NIH, Center for Disease Control, and Department of Defense funded research. His clinical research interests are in the area of prostate, bladder, and renal cancer, as well as reconstruction, and he serves as the principal investigator on numerous investigator initiated, industry funded, and institutionally funded protocols.
Dr Patrick Walsh - Johns Hopkins University, United States
Dr. Walsh is best known for his pioneering work in the development of nerve-sparing radical prostatectomy, which has reduced the probability of impotence and incontinence. He was on the editorial board of the New England Journal of Medicine for 15 years, is a member of the Institute of Medicine of the National Academy of Sciences, and in 1996 he received the Charles F. Kettering Medal from the General Motors Cancer Research Foundation for “the most outstanding recent contributions to the diagnosis and treatment of cancer.” Together with Janet F. Worthington, he authored the best-selling book for lay people Dr. Patrick Walsh’s Guide to Surviving Prostate Cancer, (Hachette Book Group (2018).